Commission renews Orange Book listing disputes, marking third round of FTC challenges to promote affordable drugs, generic competition
Continuing its efforts to promote competition and lower drug prices, today the Federal Trade Commission renewed its challenges against dozens of improperly listed device patents that shield brand-name asthma, diabetes, epinephrine autoinjector, and COPD drugs from prompt generic competition.View Press Release